Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Biovation's DeImmunization

Immunogenicity reduces efficacy of therapeutic proteins and has made it difficult to develop such molecules. Biovation Ltd. says its DeImmunization technology, which modifies T cell epitopes responsible for immunogenicity, can help solve this problem.

Last week, Biovation announced a

Read the full 388 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers